Physician profile
Matthew Stein
NPI 1639589104
$1,855.22
in general payments reported to CMS, 2019-2025
33 companies · $359 in 2025
The $359 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $210 · 2022: $278 · 2023: $642 · 2024: $367 · 2025: $359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,367.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $176.08 | 2022-2024 | Polivy, Columvi, Lunsumio |
| Abbvie INC. | $140.39 | 2022-2025 | Venclexta |
| Janssen Biotech, INC. | $125.45 | 2022-2025 | Imbruvica, Rybrevant, Darzalex |
| E.R. Squibb & Sons, L.L.C. | $123.16 | 2024-2025 | Opdivo, Opdualag |
| Merck Sharp & Dohme LLC | $110.44 | 2020-2025 | Keytruda |
| Novartis Pharmaceuticals Corporation | $107.94 | 2020-2024 | |
| Amgen INC. | $99.95 | 2020 | |
| Zimmer Biomet Holdings, INC. | $72.97 | 2024 | Mymobility Platform |
| Seagen INC. | $67.90 | 2020-2023 | Tukysa, Padcev |
| Pharmacyclics LLC, An Abbvie Company | $67.79 | 2022-2023 | Imbruvica |
| Karyopharm Therapeutics INC. | $66.79 | 2023-2024 | Xpovio |
| Regeneron Healthcare Solutions, INC. | $61.23 | 2022-2023 | Libtayo |
| Pfizer INC. | $54.61 | 2022-2025 | |
| Eisai INC. | $53.22 | 2022-2023 | |
| Glaxosmithkline, LLC. | $50.06 | 2023-2025 | Blenrep, Ojjaara, Jemperli |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Geron Corporation | $44.06 | 2025 | Rytelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.93 | 2022-2023 | Gilotrif |
| Puma Biotechnology, INC. | $42.89 | 2020-2024 | |
| Servier Pharmaceuticals LLC | $36.40 | 2024-2025 | |
| Exelixis INC. | $36.32 | 2022-2023 | Cabometyx |
| Cti Biopharma Corp. | $35.46 | 2022-2023 | Vonjo |
| Bayer Healthcare Pharmaceuticals INC. | $32.98 | 2023 | |
| Rigel Pharmaceuticals, INC. | $31.18 | 2023-2024 | Rezlidhia, Tavalisse |
| Celgene Corporation | $29.73 | 2022-2023 | Reblozyl |
| Ipsen Biopharmaceuticals, INC | $24.92 | 2024 | Onivyde |
| Takeda Pharmaceuticals U.S.A., INC. | $17.77 | 2025 | Iclusig |
| Emd Serono, INC. | $17.37 | 2025 | |
| Gilead Sciences, INC. | $16.22 | 2024 | |
| Tersera Therapeutics LLC | $15.89 | 2024 | Zoladex |
| Genzyme Corporation | $15.49 | 2025 | |
| Agios Pharmaceuticals, INC. | $14.47 | 2020 | |
| Array Biopharma INC | $11.93 | 2022 | |
| Lilly USA, LLC | $11.23 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Stein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.